DOCSLIB.ORG

Monocytes Improves Antiangiogenic Therapy in Colorectal Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monocytes Improves Antiangiogenic Therapy in Colorectal Cancer Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer Keehoon Junga,1, Takahiro Heishia,1, Joao Incioa, Yuhui Huanga, Elizabeth Y. Beecha, Matthias Pintera, William W. Hoa,b, Kosuke Kawaguchia, Nuh N. Rahbaria, Euiheon Chunga,2, Jun Ki Kimc,3, Jeffrey W. Clarkd, Christopher G. Willette, Seok Hyun Yunc,f, Andrew D. Lusterg, Timothy P. Paderaa, Rakesh K. Jaina,4,5, and Dai Fukumuraa,4,5 aEdwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114; bDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; cWellman Center for Photomedicine, Department of Dermatology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114; dDepartment of Hematology/Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114; eDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710; fDivision of Health Sciences and Technology, Harvard–Massachusetts Institute of Technology, Cambridge, MA 02139; and gCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114 Contributed by Rakesh K. Jain, August 10, 2017 (sent for review June 19, 2017; reviewed by Timothy T. Hla and Judith A. Varner) Antiangiogenic therapy with antibodies against VEGF (bevacizumab) (CXCL12)—also known as stromal cell-derived factor-1 alpha or VEGFR2 (ramucirumab) has been proven efficacious in colorectal (SDF-1α)—in primary tumor biopsies from rectal cancer patients cancer (CRC) patients. However, the improvement in overall survival treated with the anti-VEGF antibody bevacizumab compared with is modest and only in combination with chemotherapy. Thus, there baseline in the same patients (10, 11). However, the role of is an urgent need to identify potential underlying mechanisms of CXCL12/CXCR4 signaling in the resistance to anti-VEGF CRC resistance specific to antiangiogenic therapy and develop strategies therapy is not fully understood. While the role of CXCL12/CXCR4 to overcome them. Here we found that anti-VEGFR2 therapy up- regulates both C-X-C chemokine ligand 12 (CXCL12) and C-X-C chemokine receptor 4 (CXCR4) in orthotopic murine CRC models, Significance MEDICAL SCIENCES including SL4 and CT26. Blockade of CXCR4 signaling significantly enhanced treatment efficacy of anti-VEGFR2 treatment in both CRC The survival benefit of antiangiogenic therapies for cancer models. CXCR4 was predominantly expressed in immunosuppres- patients has been limited, potentially due to intrinsic/acquired sive innate immune cells, which are recruited to CRCs upon anti- resistance. Deciphering and targeting resistance mechanisms VEGFR2 treatment. Blockade of CXCR4 abrogated the recruitment are critical to improving treatment outcome, especially in can- of these innate immune cells. Importantly, these myeloid cells were cers where antiangiogenic therapies are standard of care, such mostly Ly6Clow monocytes and not Ly6Chigh monocytes. To selectively as colorectal cancer (CRC). Consistent with our clinical findings, deplete individual innate immune cell populations, we targeted key we found up-regulation of CXCL12/CXCR4 in orthotopic CRC − − pathways in Ly6Clow monocytes (Cx3cr1 / mice), Ly6Chigh monocytes models and conditional Apc mutant spontaneous rectal tumors −/− (CCR2 mice), and neutrophils (anti-Ly6G antibody) in combination after anti-VEGFR2 treatment. CXCR4 signaling recruited im- with CXCR4 blockade in SL4 CRCs. Depletion of Ly6Clow monocytes or munosuppressive innate immune cells such as Ly6Clow mono- neutrophils improved anti-VEGFR2–induced SL4 tumor growth delay cytes and Ly6G+ neutrophils to the CRCs, conferring resistance similar to the CXCR4 blockade. In CT26 CRCs, highly resistant to anti- to VEGFR2 blockade. Furthermore, we successfully targeted VEGFR2 therapy, CXCR4 blockade enhanced anti-VEGFR2–induced tu- these pathways genetically and pharmacologically, including + mor growth delay but specific depletion of Ly6G neutrophils did not. with an FDA-approved agent Plerixafor (AMD3100), which The discovery of CXCR4-dependent recruitment of Ly6Clow monocytes significantly enhanced treatment response. These strategies in tumors unveiled a heretofore unknown mechanism of resistance to have the potential for rapid clinical translation. anti-VEGF therapies. Our findings also provide a rapidly translatable strategy to enhance the outcome of anti-VEGF cancer therapies. Author contributions: K.J., A.D.L., T.P.P., R.K.J., and D.F. designed research; K.J., T.H., J.I., Y.H., E.Y.B., M.P., W.W.H., K.K., N.N.R., E.C., and J.K.K. performed research; J.W.C. and low C.G.W. contributed new reagents/analytic tools; K.J., T.H., S.H.Y., A.D.L., T.P.P., R.K.J., and tumor microenvironment | CXCR4 | Ly6C monocyte | tumor immunity | D.F. analyzed data; and K.J., S.H.Y., T.P.P., R.K.J., and D.F. wrote the paper. antiangiogenic therapy Reviewers: T.T.H., Boston Children’s Hospital and Harvard Medical School; and J.A.V., University of California, San Diego. ntivascular endothelial growth factor (anti-VEGF) therapy Conflict of interest statement: R.K.J. received consultant fees from Merck, Ophthotech, Ais widely used in many types of solid tumors and is the current Pfizer, SPARC, SynDevRx, and XTuit; owns equity in Enlight, Ophthotech, SynDevRx, and XTuit; and serves on the Board of Directors of XTuit and the Boards of Trustees of Tekla standard of care for metastatic colorectal cancer (CRC) (1). How- Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, ever, the beneficial effects from anti-VEGF therapy are often short- and Tekla World Healthcare Fund. Neither any reagent nor any funding from these lived due to intrinsic resistance and/or resistance acquired during organizations was used in this study. the treatment (1–8). Therefore, it is critical to identify mechanisms Freely available online through the PNAS open access option. and/or biomarkers of resistance to target these mechanisms and/or 1K.J. and T.H. contributed equally to this work. to stratify patients by biomarkers to improve the clinical outcome. 2Present address: Department of Medical System Engineering, School of Mechatronics, We recently found that Ly6Clow monocytes infiltrate into tumors in Gwangju Institute of Science and Technology, Gwangju 500-712, Republic of Korea. 3 a C-X3-C chemokine receptor 1 (CX3CR1)-dependent manner and Present address: Biomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea. confer resistance to anti-VEGFR2 therapy (9). However, there is 4R.K.J., and D.F. contributed equally to this work. no clinically available agent targeting this pathway, which signifi- 5To whom correspondence may be addressed. Email: [email protected] or cantly limits the possibility of clinical translation. [email protected]. We previously reported up-regulation of C-X-C chemokine This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. receptor 4 (CXCR4) and its ligand C-X-C chemokine ligand 12 1073/pnas.1710754114/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1710754114 PNAS | September 26, 2017 | vol. 114 | no. 39 | 10455–10460 Downloaded by guest on September 25, 2021 axis in regulation of immune cells has been investigated, including we have previously shown (9), SL4 and CT26 tumor size was ∼45% a subset of monocytes (i.e., Ly6Chigh monocytes) (12–17), whether and ∼70% of that of the control after 12 d of DC101 monotherapy CXCR4 is involved in regulation of another subset of monocytes (Fig. 1 G and H). In addition, the extent of tumor growth inhibition (i.e., Ly6Clow monocytes) is not known. by the combined therapy was similar in both SL4 and CT26 models. In this study, building on our previous clinical finding that These data indicate that the mechanism making CT26 less sensitive CXCR4 is up-regulated in rectal cancer postbevacizumab ther- to anti-VEGFR2 treatment was abolished by the blockade of apy, we targeted CXCR4 using AMD3100, an FDA approved CXCR4. These data show that targeting CXCR4 enhances the ef- agent, which resulted in significant improvement of anti-VEGFR2 ficacy of antiangiogenic therapy in both CRC models, regardless of therapy in clinically relevant orthotopic murine CRC models. their sensitivity to anti-VEGFR2 monotherapy. Mechanistically, we found that CXCR4 is critical for tumor infiltration of Ly6Clow monocytes and that blockade of Ly6Clow Blockade of CXCR4 Alleviates Anti-VEGFR2 Therapy-Induced Lymphocyte monocyte recruitment improves the efficacy of anti-VEGFR2 Reduction but Does Not Directly Affect Tumor Cell Proliferation. Next, therapy in CRCs. Thus, targeting CXCR4-mediated Ly6Clow we sought the mechanisms of how the blockade of CXCR4 en- monocyte infiltration is a potential strategy to enhance the ef- hances the antitumor effect of anti-VEGFR2 therapy. First, we ficacy of anti-VEGF treatments for CRC patients. tested whether the blockade of CXCR4 directly inhibited pro- liferation of cancer cells themselves. MTT (methyl thiazolyl tet- Results razolium) assay results showed that CXCR4 is not involved in the Antiangiogenic Therapy Increases Expression of CXCL12 and CXCR4 in regulation of colon cancer cell proliferation (Fig.
Load more

Recommended publications
  • An Endocytosis Pathway Initiated Through Neuropilin-1 and Regulated by Nutrient Availability
    ARTICLE Received 18 Apr 2014 | Accepted 2 Aug 2014 | Published 3 Oct 2014 DOI: 10.1038/ncomms5904 An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability Hong-Bo Pang1, Gary B. Braun1,2, Tomas Friman1,2, Pedro Aza-Blanc1, Manuel E. Ruidiaz1, Kazuki N. Sugahara1,3, Tambet Teesalu1,4 & Erkki Ruoslahti1,2 Neuropilins (NRPs) are trans-membrane receptors involved in axon guidance and vascular development. Many growth factors and other signalling molecules bind to NRPs through a carboxy (C)-terminal, basic sequence motif (C-end Rule or CendR motif). Peptides with this motif (CendR peptides) are taken up into cells by endocytosis. Tumour-homing CendR peptides penetrate through tumour tissue and have shown utility in enhancing drug delivery into tumours. Here we show, using RNAi screening and subsequent validation studies, that NRP1-mediated endocytosis of CendR peptides is distinct from known endocytic pathways. Ultrastructurally, CendR endocytosis resembles macropinocytosis, but is mechanistically different. We also show that nutrient-sensing networks such as mTOR signalling regulate CendR endocytosis and subsequent intercellular transport of CendR cargo, both of which are stimulated by nutrient depletion. As CendR is a bulk transport pathway, our results suggest a role for it in nutrient transport; CendR-enhanced drug delivery then makes use of this natural pathway. 1 Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA. 2 Center for Nanomedicine, Department of Cell, Molecular and Developmental Biology, University of California Santa Barbara, Santa Barbara, California 93106-9610, USA. 3 Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA.
    [Show full text]
  • Exploring the Extracellular Regulation of the Tumor Angiogenic Interaction
    bioRxiv preprint doi: https://doi.org/10.1101/581884; this version posted March 18, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Exploring the extracellular regulation of the tumor angiogenic in- teraction network using a systems biology model Ding Li1 and Stacey D. Finley2 1Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA 2Department of Biomedical Engineering; Mork Family Department of Chemical Engineering and Materials Sci- ence; Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA ABSTRACT angiogenic signaling to oppose angiogenesis4,5. Considering Tumor angiogenesis is regulated by pro- and anti-angiogenic factors. the importance of angiogenesis in tumor development, anti- Anti-angiogenic agents target the interconnected network of angio- angiogenic therapies are designed to target the signaling of genic factors to inhibit neovascularization, which subsequently im- angiogenic factors to inhibit neovascularization and tumor pedes tumor growth. Due to the complexity of this network, optimizing growth6. Single-agent anti-angiogenic therapies that target a anti-angiogenic cancer treatments requires detailed knowledge at a particular angiogenic factor in the network were the first angi- systems level. In this study, we constructed a tumor tissue-based ogenesis-inhibiting therapies studied. These include antibod- model to better understand how the angiogenic network is regulated ies or small molecules targeting pro-angiogenic factors7 and by opposing mediators at the extracellular level. We consider the net- peptide mimetics of anti-angiogenic factors8.
    [Show full text]
  • Neuropilin-1
    November 3, 2020 Edition 2020-11-03 *** Available on-line at https://www.cdc.gov/library/covid19 *** Neuropilin-1 The SARS-CoV-2 major spike protein (S) is cleaved by a host protease to create S1 and S2 functional polypeptides. The S1 polypeptide has a carboxy-terminal sequence that binds to host cell surface neuropilin-1 (NRP1) and neuropilin-2 (NRP2) receptors. NRP receptors facilitate viral entry for several viruses due to their abundance on cells that are exposed to the external environment – cells that paradoxically express low levels of angiotensin- converting enzyme-2 (ACE2), the known SARS-CoV-2 receptor. Here we present two articles that evaluated the potential for NRP1 to act as a co-receptor for SARS-CoV-2. PEER-REVIEWED Neuropilin-1 is a host factor for SARS-CoV-2 infection. Daly et al. Science (October 20, 2020). Key findings: • The S1 fragment of the cleaved SARS-CoV-2 spike protein binds to the cell surface receptor neuropilin-1 (NRP1). • SARS-CoV-2 utilizes NRP1 for cell entry as evidenced by decreased infectivity of cells in the presence of: o NRP1 deletion (p <0.0001) (Figure). o Three different anti-NRP1 monoclonal antibodies (p <0.001). o Selective NRP1 antagonist, EG00229 (p <0.01). Methods: Binding of the S1 fragment to NRP1 was assessed and ability of SARS-CoV-2 to use NRP1 to infect cells was measured in angiotensin-converting enzyme-2 (ACE-2)-expressing cell lines by knocking out NRP1 expression, blocking NRP1 with 3 different anti-NRP1 monoclonal antibodies, or using NRP1 small molecule antagonists.
    [Show full text]
  • Microrna-320A Inhibits Tumor Invasion by Targeting Neuropilin 1 and Is Associated with Liver Metastasis in Colorectal Cancer
    ONCOLOGY REPORTS 27: 685-694, 2012 microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer YUJUN ZHANG1, XIANGJUN HE1, YULAN LIU1,2, YINGJIANG YE3, HUI ZHANG3, PEIYING HE1, QI ZHANG1, LINGYI DONG3, YUJING LIU1 and JIANQIANG DONG1 1Institute of Clinical Molecular Biology, and Departments of 2Gastroenterology and 3General Surgery, Peking University, People's Hospital, Beijing 100044, P.R. China Received September 13, 2011; Accepted October 26, 2011 DOI: 10.3892/or.2011.1561 Abstract. MicroRNAs (miRNAs) have been implicated Introduction in regulating diverse cellular pathways. Although there is emerging evidence that various miRNAs function as onco- Colorectal cancer (CRC) is the second most common cause genes or tumor suppressors in colorectal cancer (CRC), the role of cancer-related death worldwide (1). Approximately 50% of of miRNAs in mediating liver metastasis remains unexplored. patients diagnosed with CRC die as a result of complications The expression profile of miRNAs in liver metastasis and from distant metastases, which occur mainly in the liver. The primary CRC tissues was analyzed by miRNA microarrays occurrence of liver metastasis ranges from 20% in stage II to and verified by real-time polymerase chain reaction (PCR). 70% in stage IV CRC patients, according to the UICC stage In 62 CRC patients, the expression levels of miR-320a were guidelines. Of all patients who die of advanced colorectal determined by real-time PCR, and the effects on migration and cancer (ACRC), 60-70% display liver metastasis (2). Metastasis invasion of miR-320a were determined using a transwell assay. to the liver is the major cause of death in CRC patients (3).
    [Show full text]
  • A Dominant Negative Receptor for Specific
    The Journal of Neuroscience, September 15, 1999, 19(18):7870–7880 A Dominant Negative Receptor for Specific Secreted Semaphorins Is Generated by Deleting an Extracellular Domain from Neuropilin-1 Michael J. Renzi, Leonard Feiner, Adam M. Koppel, and Jonathan A. Raper Department of Neurosciences, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6074 Neuropilins have recently been characterized as receptors for plasmic domain fails to act as a dominant negative receptor secreted semaphorins. Here, we report the generation of a component. These results suggest that neuropilin-1 is a nec- dominant negative form of neuropilin-1 by the deletion of one of essary component of receptor complexes for some, but not all, its extracellular domains. Expression of this variant in cultured secreted semaphorin family members. Overexpression of dom- primary sympathetic neurons blocks the paralysis of growth inant negative neuropilins should provide a powerful new cone motility normally induced by SEMA-3A (collapsin-1, method of blocking the functions of secreted semaphorins. semaphorin III, semaphorin D) and SEMA-3C (collapsin-3, Key words: semaphorin; collapsin; neuropilin-1; sympathetic semaphorin E) but not that induced by SEMA-3F (semaphorin neuron; growth cone guidance; growth cone collapse; domi- IV). A truncated form of neuropilin-1 that is missing its cyto- nant negative receptor The development of a functional nervous system requires that Giger et al., 1998a,b) and are likely to act as repellents that help axons navigate through a complex environment, sometimes over guide peripheral axons, particularly sympathetic axons, along long distances, to locate their correct targets. At the growing tips their appropriate trajectories.
    [Show full text]
  • Signals of the Neuropilin-1–MET Axis and Cues of Mechanical Force Exertion Converge to Elicit Inflammatory Activation in Coherent Endothelial Cells
    Signals of the Neuropilin-1−MET Axis and Cues of Mechanical Force Exertion Converge to Elicit Inflammatory Activation in Coherent Endothelial Cells This information is current as of September 27, 2021. Maryam Rezaei, Ana C. Martins Cavaco, Jochen Seebach, Stephan Niland, Jana Zimmermann, Eva-Maria Hanschmann, Rupert Hallmann, Hermann Schillers and Johannes A. Eble J Immunol published online 28 January 2019 Downloaded from http://www.jimmunol.org/content/early/2019/01/27/jimmun ol.1801346 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2019/01/27/jimmunol.180134 Material 6.DCSupplemental Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published January 28, 2019, doi:10.4049/jimmunol.1801346 The Journal of Immunology Signals of the Neuropilin-1–MET Axis and Cues of Mechanical Force Exertion Converge to Elicit Inflammatory Activation in Coherent Endothelial Cells Maryam Rezaei,* Ana C.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Epigenetic Targeting of Neuropilin-1 Prevents Bypass Signaling in Drug-Resistant Breast Cancer
    Oncogene (2021) 40:322–333 https://doi.org/10.1038/s41388-020-01530-6 ARTICLE Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer 1 1 1 1 1 2 Ammara Abdullah ● Saeed Salehin Akhand ● Juan Sebastian Paez Paez ● Wells Brown ● Li Pan ● Sarah Libring ● 1 1,3 2,3 1,3 1,3 Michael Badamy ● Emily Dykuizen ● Luis Solorio ● W. Andy Tao ● Michael K. Wendt Received: 20 April 2020 / Revised: 13 October 2020 / Accepted: 15 October 2020 / Published online: 30 October 2020 © The Author(s) 2020. This article is published with open access Abstract Human epidermal growth factor receptor 2 (HER2)-amplified breast cancers are treated using targeted antibodies and kinase inhibitors, but resistance to these therapies leads to systemic tumor recurrence of metastatic disease. Herein, we conducted gene expression analyses of HER2 kinase inhibitor-resistant cell lines as compared to their drug-sensitive counterparts. These data demonstrate the induction of epithelial–mesenchymal transition (EMT), which included enhanced expression of fibroblast growth factor receptor 1 (FGFR1) and axonal guidance molecules known as neuropilins (NRPs). Immunoprecipitation of FGFR1 coupled with mass spectroscopy indicated that FGFR1 forms a physical complex with NRPs, which is enhanced upon 1234567890();,: 1234567890();,: induction of EMT. Confocal imaging revealed that FGFR1 and NRP1 predominantly interact throughout the cytoplasm. Along these lines, short hairpin RNA-mediated depletion of NRP1, but not the use of NRP1-blocking antibodies, inhibited FGFR signaling and reduced tumor cell growth in vitro and in vivo. Our results further indicate that NRP1 upregulation during EMT is mediated via binding of the chromatin reader protein, bromodomain containing 4 (BRD4) in the NRP1 proximal promoter region.
    [Show full text]
  • CD304 (BDCA-4/ Neuropilin-1) Microbead
    CD304 (BDCA-4/ Neuropilin-1) MicroBead Kit human Order no. 130-090-532 Contents 1.2 Background information 1. Description CD304 (BDCA-4/Neuropilin-1)1 is specifically expressed by – 1.1 Principle of the MACS® Separation plasmacytoid dendritic cells (PDCs) in human peripheral blood¹ ⁵, cord blood¹², and bone marrow⁶. Exclusive expression of CD304 1.2 Background information (BDCA-4/Neuropilin-1) on plasmacytoid dendritic cells allows their 1.3 Applications direct isolation by positive selection. In blood and bone marrow, CD304 (BDCA-4/Neuropilin-1)+ plasmacytoid dendritic cells are 1.4 Reagent and instrument requirements characterized as being CD11c–, CD123high, CD4+, CD45RA+, CD303 2. Protocol (BDCA-2)+, CD141 (BDCA-3)dim, CD1c (BDCA-1)–, and CD2–. 2.1 Sample preparation They lack expression of lineage markers (CD3, CD14, CD16, CD19, CD20, CD56), and express neither myeloid markers, like CD13 and 2.2 Magnetic labeling CD33, nor Fc receptors, such as CD32, CD64, or FcεRI. Freshly 2.3 Magnetic separation isolated CD1c (BDCA-1)+ or CD141 (BDCA-3)++ blood dendritic cells and monocytes do not express CD304 (BDCA-4/Neuropilin- 3. Example of a separation using the CD304 (BDCA-4/ 1) but expression of CD304 (BDCA-4/Neuropilin-1) is induced Neuropilin-1) MicroBead Kit in culture.¹,⁶ In inflamed tonsils, CD304 (BDCA-4/Neuropilin-1) 4. References expression is, apart from plasmacytoid dendritic cells, also detected on some other cells, primarily follicular B helper memory T cells.6 Additionally, Neuropilin-1 is known to be expressed on numerous 1. Description non-hematopoietic cell types, e.g. neurons, endothelial and tumor cells.
    [Show full text]
  • Molecular Signatures Differentiate Immune States in Type 1 Diabetes Families
    Page 1 of 65 Diabetes Molecular signatures differentiate immune states in Type 1 diabetes families Yi-Guang Chen1, Susanne M. Cabrera1, Shuang Jia1, Mary L. Kaldunski1, Joanna Kramer1, Sami Cheong2, Rhonda Geoffrey1, Mark F. Roethle1, Jeffrey E. Woodliff3, Carla J. Greenbaum4, Xujing Wang5, and Martin J. Hessner1 1The Max McGee National Research Center for Juvenile Diabetes, Children's Research Institute of Children's Hospital of Wisconsin, and Department of Pediatrics at the Medical College of Wisconsin Milwaukee, WI 53226, USA. 2The Department of Mathematical Sciences, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, USA. 3Flow Cytometry & Cell Separation Facility, Bindley Bioscience Center, Purdue University, West Lafayette, IN 47907, USA. 4Diabetes Research Program, Benaroya Research Institute, Seattle, WA, 98101, USA. 5Systems Biology Center, the National Heart, Lung, and Blood Institute, the National Institutes of Health, Bethesda, MD 20824, USA. Corresponding author: Martin J. Hessner, Ph.D., The Department of Pediatrics, The Medical College of Wisconsin, Milwaukee, WI 53226, USA Tel: 011-1-414-955-4496; Fax: 011-1-414-955-6663; E-mail: [email protected]. Running title: Innate Inflammation in T1D Families Word count: 3999 Number of Tables: 1 Number of Figures: 7 1 For Peer Review Only Diabetes Publish Ahead of Print, published online April 23, 2014 Diabetes Page 2 of 65 ABSTRACT Mechanisms associated with Type 1 diabetes (T1D) development remain incompletely defined. Employing a sensitive array-based bioassay where patient plasma is used to induce transcriptional responses in healthy leukocytes, we previously reported disease-specific, partially IL-1 dependent, signatures associated with pre and recent onset (RO) T1D relative to unrelated healthy controls (uHC).
    [Show full text]
  • VEGFR2 Survival and Mitotic Signaling Depends on Joint Activation of Associated C3ar1/C5ar1 and IL-6R–Gp130 Ming-Shih Hwang1,*, Michael G
    © 2019. Published by The Company of Biologists Ltd | Journal of Cell Science (2019) 132, jcs219352. doi:10.1242/jcs.219352 RESEARCH ARTICLE VEGFR2 survival and mitotic signaling depends on joint activation of associated C3ar1/C5ar1 and IL-6R–gp130 Ming-Shih Hwang1,*, Michael G. Strainic1,*, Elliot Pohlmann1, Haesuk Kim1, Elzbieta Pluskota2, Diana L. Ramirez-Bergeron3, Edward F. Plow2 and M. Edward Medof1,‡ ABSTRACT signaling thus has broad importance biologically as well as Purified vascular endothelial cell (EC) growth factor receptor-2 clinically. (VEGFR2) auto-phosphorylates upon VEGF-A occupation in vitro, Previous studies reported (Albrecht et al., 2004; Laudes et al., arguing that VEGR2 confers its mitotic and viability signaling in and of 2002) that ECs can synthesize complement component C3, that itself. Herein, we show that, in ECs, VEGFR2 function requires the complement activation fragment C5a can affect EC responses concurrent C3a/C5a receptor (C3ar1/C5ar1) and IL-6 receptor in vitro, and that the generation of C3a and/or C5a activation (IL-6R)–gp130 co-signaling. C3ar1/C5ar1 or IL-6R blockade totally fragments accompanies numerous disease states (Alawieh et al., abolished VEGFR2 auto-phosphorylation, downstream Src, ERK, 2015; Lillegard et al., 2014; Facciabene et al., 2017; Lechner et al., AKT, mTOR and STAT3 activation, and EC cell cycle entry. VEGF-A 2016; Wu et al., 2017). These findings uniformly were interpreted in augmented production of C3a/C5a/IL-6 and their receptors via a the context of systemic complement activation. We previously two-step p-Tyk2/p-STAT3 process. Co-immunoprecipitation analyses, implicated C3a and C5a receptor (C3ar1 and C5ar1) signaling in the confocal microscopy, ligand pulldown and bioluminescence EC response to vascular wire injury (Sakuma et al., 2010) and, like resonance energy transfer assays all indicated that the four other studies, presumed that the C3a and C5a ligands derived from receptors are physically interactive.
    [Show full text]
  • Cell TLR7 Activation and Plasmacytoid Dendritic CXCL13 Secretion in Human Monocytes Via HIV-1 Single-Stra
    HIV-1 Single-Stranded RNA Induces CXCL13 Secretion in Human Monocytes via TLR7 Activation and Plasmacytoid Dendritic Cell −Derived Type I IFN This information is current as of October 2, 2021. Kristen W. Cohen, Anne-Sophie Dugast, Galit Alter, M. Juliana McElrath and Leonidas Stamatatos J Immunol 2015; 194:2769-2775; Prepublished online 9 February 2015; doi: 10.4049/jimmunol.1400952 Downloaded from http://www.jimmunol.org/content/194/6/2769 References This article cites 49 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/194/6/2769.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 2, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology HIV-1 Single-Stranded RNA Induces CXCL13 Secretion in Human Monocytes via TLR7 Activation and Plasmacytoid Dendritic Cell–Derived Type I IFN Kristen W.
    [Show full text]